View source for BIT225

{{Chembox
| ImageFile = BIT225.svg
|  ImageSize = 200px
|  ImageAlt =
| IUPACName = ''N''-Carbamimidoyl-5-(1-methyl-1''H''-pyrazol-4-yl)-2-naphthamide
| OtherNames = BIT-225
| Section1 = {{Chembox Identifiers
|  CASNo = 917909-71-8
| CASNo_Ref = {{cascite|correct|CAS}}
| UNII_Ref = {{fdacite|correct|FDA}}
| UNII = M9C27TI12U
|  PubChem = 12004418
|  ChemSpiderID = 10176885
|  SMILES = CN1C=C(C=N1)C2=CC=CC3=C2C=CC(=C3)C(=O)NC(=N)N
|  InChI = 1/C16H15N5O/c1-21-9-12(8-19-21)13-4-2-3-10-7-11(5-6-14(10)13)15(22)20-16(17)18/h2-9H,1H3,(H4,17,18,20,22)
|  InChIKey = WVROWPPEIMRGAB-UHFFFAOYAP
|  StdInChI = 1S/C16H15N5O/c1-21-9-12(8-19-21)13-4-2-3-10-7-11(5-6-14(10)13)15(22)20-16(17)18/h2-9H,1H3,(H4,17,18,20,22)
|  StdInChIKey = WVROWPPEIMRGAB-UHFFFAOYSA-N
}}
| Section2 = {{Chembox Properties
|  C=16|H=15|N=5|O=1
|  Appearance =
|  Density =
|  MeltingPt =
|  BoilingPt =
|  Solubility =
}}
| Section3 = {{Chembox Hazards
|  MainHazards =
|  FlashPt =
|  AutoignitionPt =
}}
}}
'''BIT225''' is an experimental drug candidate under development by Biotron Limited for use in the treatment of both [[HIV]] and [[hepatitis C]] infection. By blocking [[Vpu]] ion channel activity, it disrupts HIV assembly within host [[monocyte]] cells; its [[method of action]] is a first for HIV drugs.<ref>[http://pag.aids2014.org/Abstracts.aspx?AID=3411 BIT225 therapy reduces HIV-1 burden in monocyte cells and decreases immune activation]</ref> Because it targets replication in [[monocyte]] derived [[macrophages]], it offers promise for treatment of viral reservoirs that are unaffected by standard treatments.<ref>[http://www.natap.org/2013/IAS/IAS_47.htm BIT225, a Novel Assembly Inhibitor, Cuts HIV Load in Monocyte Reservoir]</ref> The activity of BIT225 is post-virus integration, with no direct effects on the HIV enzymes [[reverse transcriptase]] and [[protease]].<ref>[http://aac.asm.org/content/54/2/835.abstract Antiviral Efficacy of the Novel Compound BIT225 against HIV-1 Release from Human Macrophages]</ref> Since Vpu ion channel activity is highly conserved, the virus is unlikely to become resistant via generation of Vpu ion-independent virus. In addition, the drug also has been credited with curing [[hepatitis C]] after 12 weeks of treatment.<ref>[http://www.dddmag.com/news/2014/10/bit225-trial-results-show-effective-cure-hepatitis-c BIT225 Trial Results Show Effective Cure of Hepatitis C]</ref>
==References==
{{reflist}}
{{HIVpharm}}
[[Category:Antiretroviral drugs]]
[[Category:Pyrazoles]]
[[Category:Acylguanidines]]
[[Category:Experimental antiviral drugs]]